AUTOCAST – Your path to advanced diabetic foot therapy.

In a world where diabetes affects millions, the prevalence of diabetic foot ulcers remains a critical challenge. Diabetic foot complications, including ulcers, affect individuals globally, posing significant risks to their well-being. AUTOCAST emerges as a beacon of innovation, addressing the urgent need for advanced diabetic foot therapy solutions.

The staggering rise in diabetes cases worldwide has amplified the importance of proactive and effective management, especially concerning diabetic foot ulcers. These ulcers, if left unattended, can lead to severe complications, impacting the overall health and mobility of individuals living with diabetes.

AUTOCAST is not merely a product; it represents a transformative approach to diabetic foot care. By seamlessly integrating cutting-edge technology, personalized features, and real-time monitoring capabilities, AUTOCAST strives to redefine the narrative of diabetic foot therapy. Our mission is rooted in enhancing the lives of those navigating the complexities of diabetes, offering a path to improved health outcomes and a better quality of life.

Embark on this journey with AUTOCAST – where innovation meets compassion, and each step forward is a stride towards a future where diabetic foot ulcers are effectively managed, and individuals can thrive despite the challenges posed by diabetes.

Meet team

Complexities of Diabetic Foot Ulcers

Diabetic foot ulcers (DFUs) pose a significant and often debilitating complication of diabetes, with profound implications for individuals’ well-being. According to insights published in the Diabetes Care journal, the lifetime risk of developing a DFU ranges from 19% to 34%1. The intricate pathway leading to ulceration, characterized by the loss of sensation, ischemia, and minor trauma, is well-documented. The ramifications of foot ulcers are extensive, encompassing a decline in functional status, heightened infection risks, hospitalization, lower-extremity amputation, and, in severe cases, even mortality1.

Compounding the challenge, the review underscores that morbidity following incident ulceration remains high, with recurrence rates soaring to 65% at 3–5 years, a lifetime incidence of lower-extremity amputation at 20%, and a sobering 5-year mortality rate of 50–70%1. Recent data signal a concerning increase in overall amputation incidence by up to 50% in certain regions over the past several years, marking a reversal from a prolonged period of decline, especially affecting young individuals and diverse racial and ethnic minority populations1.

The imperative for prevention and early detection of DFUs through guideline-directed multidisciplinary care has never been more critical. This proactive approach is indispensable in mitigating the morbidity and disparities associated with DFUs, representing a pivotal step towards improving the overall outlook for individuals grappling with the complexities of diabetes.


Meet our team of Innovators

Discover the driving force behind AUTOCAST—Martyna Jakubowska, our R&D Project Manager specializing in IP rights; Konrad Jakubowski, a Medical Doctor and Orthopedic Surgeon serving as a crucial Medical Advisor; Mateusz Dworak, our Medical Doctor focused on Clinical Trials and medical advisory roles; and Błażej Żyliński, spearheading Product Traction and Research & Development.

Together, we’re dedicated to transforming our idea into action, bringing a revolutionary diabetic foot therapy solution to life. Our diverse skills converge to ensure AUTOCAST not only innovates but also improves lives. Join us as we navigate the journey from concept to reality, reshaping diabetic foot care through relentless dedication and expertise.

Have any questions or ideas?